Quantum-Si (QSI) H.C. Wainwright 4th Annual BioConnect Investor Conference summary

Strategic direction and product roadmap

• Focus shifted from first-generation Platinum to developing and launching Proteus, a next-generation protein sequencing platform, with commercial readiness targeted for late 2024 and a multi-year evolution planned through chemistry and software upgrades.

• Proteus will launch with 80 million wells, with future versions (Proteus Plus and Proteus 2.0) scaling up to 320 million and potentially 10 billion wells, respectively, primarily through consumable and software improvements rather than new hardware.

• Customers investing in Proteus will benefit from ongoing enhancements without needing to purchase new hardware, as most upgrades will be delivered via software or consumable updates.

• The company is leveraging learnings from Platinum’s broad launch to ensure a more focused and controlled rollout for Proteus, emphasizing post-translational modifications (PTMs) and single amino acid variant detection.

• A summer program will place Proteus at select sites to generate early data and publications, supporting market awareness and validation ahead of full commercial launch.

Technology and capabilities

• Proteus achieves approximately double the read length of Platinum, with current average read lengths around 15 amino acids, enhancing detection of PTMs and single amino acid variants.

• The platform can currently detect 17 out of 20 amino acids and is designed to maximize coverage, improving the breadth and depth of proteomic analysis.

• PTM detection is a key differentiator, with kinetic signature-based detection enabling rapid expansion of detectable PTMs via software updates, making the system highly extensible.

• Proteus aims to address both research and manufacturing markets, supporting broad PTM profiling for research and focused PTM detection for manufacturing quality control.

• Automated workflows and integrated analysis tools are being developed to streamline PTM detection and reporting, reducing reliance on third-party software.

Commercial strategy and market positioning

• Proteus is priced at $425,000, with no significant pushback from potential customers, and the company is open to future price adjustments based on market response.

• The sales team has been actively prospecting globally, gathering hundreds of data points on customer needs and building a pipeline for launch.

• The company anticipates a controlled adoption curve, with purchasing decisions influenced by budget cycles, grant approvals, and sample validation, rather than a sudden surge at launch.

• Early access programs and sample processing services are being used to build customer confidence and generate reference data ahead of broader rollout.

• The company is leveraging industry events, workshops, and publications to disseminate early results and drive awareness.